Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study

BackgroundThe CAPRICE trial was designed to specifically evaluate neoadjuvant pegylated liposomal doxorubicin (PLD) in elderly patients or in those with other cardiovascular risk factors in whom conventional doxorubicin was contraindicated. The primary analysis of the study showed a pathological com...

Full description

Bibliographic Details
Main Authors: Miguel J. Gil-Gil, Meritxell Bellet, Milana Bergamino, Serafín Morales, Agustí Barnadas, Luís Manso, Cristina Saura, Adela Fernández-Ortega, Elena Garcia-Martinez, Noelia Martinez-Jañez, Mireia Melé, Patricia Villagrasa, Pamela Celiz, X. Perez Martin, Eva Ciruelos, Sonia Pernas
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
pegylated liposomal doxorubicin
elderly
neoadjuvant chemotherapy
triple negative breast cancer
long-term results
cardiotoxicity
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.645026/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.645026/full

Similar Items